Jean M. Connors, MD, of Brigham and Women’s Hospital, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss a roundup of key findings on a critical area in the treatment of hematologic malignancies (Abstracts 17, 85, 86, 135, 139, 143, 273, 415, 419, 719, 877, 880).
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses phase I study findings on nivolumab in combination with ipilimumab for relapsed or refractory disease (Abstract 183).
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Nelli Bejanyan, MD, of the University of Minnesota, discuss findings from a study conducted by the Center for International Blood and Marrow Transplant Research on treatment for ALL patients, with an available donor, undergoing myeloablative allogeneic hematopoietic cell transplantation in first complete remission (Abstract 684).
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses agents in the pipeline for follicular lymphoma, including drugs targeting the immune microenvironment, novel monoclonal antibodies, and emerging immunotherapeutics.
Joshua Brody, MD, of the Icahn School of Medicine at Mount Sinai, summarizes important data on passive and active immunotherapy (Abstracts 1213, 1214, 1215, 1216, 1217, 1218).
Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).
